Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis

This article was originally published here

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021. Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection

The post Lupin announces FDA filing acceptance of sNDA for Solosec to treat trichomoniasis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply